The Full Wiki

More info on PRX-00023

PRX-00023: Wikis

Advertisements

Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.

Encyclopedia

From Wikipedia, the free encyclopedia

PRX-00023
Systematic (IUPAC) name
N-(3-[4-(4-cyclohexylmethanesulfonylaminobutyl)piperazin-1-yl]phenyl)acetamide
Identifiers
ATC code none
PubChem 11430856
Chemical data
Formula C23H38N4O3S 
Mol. mass 450.636 g/mol
SMILES eMolecules & PubChem
Therapeutic considerations
Pregnancy cat.  ?
Legal status

PRX-00023 is a drug that was being developed by EPIX Pharmaceuticals Inc for the treatment of generalized anxiety disorder and major depressive disorder.[1][2] It was well tolerated in clinical trials but failed to reach significant remission on the Hammilton Rating Scales and development was subsequently discontinued.[2][3][4]

PRX-00023 acts as a selective 5-HT1A receptor ligand and sigma receptor agonist.[2][5][6] Originally believed to have appreciable intrinsic activity as an agonist of the 5-HT1A receptor, later studies found it to possess very low efficacy (6-7% relative to 5-HT) and to behave more like an antagonist, likely underlying its failure as an antidepressant/anxiolytic in clinical trials.[7]

References

  1. ^ de Paulis T. (2007). "Drug evaluation: PRX-00023, a selective 5-HT1A receptor agonist for depression.". Curr Opin Investig Drugs. 8 (1): 78–86. PMID 17263189. 
  2. ^ a b c Rickels K, Mathew S, Banov MD, Zimbroff DL, Oshana S, Parsons EC Jr, Donahue SR, Kauffman M, Iyer GR, Reinhard JF Jr. (2008). "Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial.". J Clin Psychopharmacol. 28 (2): 235–239. PMID 18344738. 
  3. ^ de Paulis T. (2007). "Tolerability, pharmacokinetics, and neuroendocrine effects of PRX-00023, a novel 5-HT1A agonist, in healthy subjects.". J Clin Pharmacol. 47 (7): 817–824. PMID 17495280. 
  4. ^ Mathew SJ, Garakani A, Reinhard JF Jr, Oshana S, Donahue S. (2008). "Short-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: a 28-day, open-label study.". Clin Ther. 30 (9): 1658–1666. PMID 18840371. 
  5. ^ Becker OM, Dhanoa DS, Marantz Y, Chen D, Shacham S, Cheruku S, Heifetz A, Mohanty P, Fichman M, Sharadendu A, Nudelman R, Kauffman M, Noiman S. (2006). "An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression.". J Med Chem. 49 (11): 3116–3135. PMID 16722631. 
  6. ^ Prof John Kelly (2010). Principles of CNS Drug Development: From Test Tube to Patient. New York: Wiley. ISBN 0-470-51979-7. http://books.google.com/books?id=pfY3xcsu6EsC&lpg=PA265&dq=adatanserin&as_brr=3&pg=PA265#v=onepage&q=PRX-00023&f=false. 
  7. ^ Maurel JL, Autin JM, Funes P, Newman-Tancredi A, Colpaert F, Vacher B (October 2007). "High-efficacy 5-HT1A agonists for antidepressant treatment: a renewed opportunity". Journal of Medicinal Chemistry 50 (20): 5024–33. doi:10.1021/jm070714l. PMID 17803293. http://dx.doi.org/10.1021/jm070714l. 
Advertisements

Advertisements






Got something to say? Make a comment.
Your name
Your email address
Message